All GLP-1 receptor agonists carry a black-box warning for risk of thyroid C-cell tumors based on rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2. Rare but serious adverse events include pancreatitis, gallbladder disease, and gastroparesis.